Get the Weekly Intelligence Brief — top committee picks every Sunday.

ARGX vs RARE

argenx SE vs Ultragenyx Pharmaceutical Inc. — AI-powered side-by-side comparison
ARGX
argenx SE
69
Buy
VS
RARE
Ultragenyx Pharmaceutical Inc.
56
Watch
MetricARGXRARE
AI Score 69 56
Price $864.40 $26.96
P/E Ratio 31.34× -4.62×
ROE 17.6% 718.8%
Revenue Growth YoY
Gross Margin 89.9% 83.1%
Debt / Equity 0.01× -4.13×
Dividend Yield 0.0% 0.0%
RSI (14) 47.9 54.3
Beta -0.022 0.313
Expected Upside

AI Committee View

Current Innellis committee reasoning for ARGX versus RARE.
ARGX leads by 13 points.

ARGX scores 69/100 (Buy) versus RARE at 56/100 (Watch).

ARGX Committee View
67% agreement
6 analysts

The primary driver is revenue growing 71.3% yoy -- genuine top-line momentum. The main limiting factor is price-to-book of 6.9x prices in significant intangible value. The committee is constructive but not yet at full conviction.

Bull Case
  • ROE of 22.4% shows genuine earnings power backing the valuation — Value
  • Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
  • EPS growing 95.7% YoY — Growth
Bear Case
  • Price-to-book of 6.9x prices in significant intangible value — Value
  • MACD histogram negative -- bearish momentum — Technical
RARE Committee View
50% agreement
4 analysts

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 27.5% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
  • Price structure making lower highs and lower lows — Technical
  • Price structure (HH_HL) contradicts the downtrend -- mixed signals — Technical
  • Bollinger bandwidth of 27.5% signals elevated volatility — Risk
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
ARGX Full Analysis RARE Full Analysis